NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT06819007 2026-03-05
DO-01
Daiichi Sankyo
Phase 3 Recruiting
NCT06890338 2026-02-24
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting